Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Targeted treatment of AML using T cell recruiting antibody constructs

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany
Targeted treatment of AML using T cell recruiting antibody constructs ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )
19 Jun 2019

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
18 Jun 2019

The potential of PARP inhibitors in new cancer groups and in combination with other treatments

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA
The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2019

Are PARP inhibitors a new standard of care option for MBC patients?

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA
Are PARP inhibitors a new standard of care option for MBC patients? ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2019

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Dr Joel Neal - Stanford University, Stanford, USA
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )
18 Jun 2019

Cutting-edge cancer care at the Miami Cancer Institute

Dr Miguel Villalona - Miami Cancer Institute, Miami, USA
Cutting-edge cancer care at the Miami Cancer Institute ( Dr Miguel Villalona - Miami Cancer Institute, Miami, USA )
18 Jun 2019

Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia

Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands
Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia ( Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands )
15 Jun 2019

Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities

Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands
Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities ( Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands )
15 Jun 2019

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
15 Jun 2019

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia

Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia ( Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
15 Jun 2019

Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM

Dr Shaji Kumar - Mayo Clinic, Rochester, USA
Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
15 Jun 2019

Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry

Dr Ekaterina Chelysheva - National Research Center for Hematology, Moscow, Russian Federation
Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry ( Dr Ekaterina Chelysheva -  National Research Center for Hematology, Moscow, Russian Federation )
14 Jun 2019